Chronicle Bio, Inc. filed an amended Form D with the Securities and Exchange Commission on 2025-10-15.
Chronicle Bio, Inc. filed an amended Form D notice of an exempt securities offering with the SEC on October 15, 2025. The filing reports $10.27M sold. Its industry group is Other Technology. It names Rohit Gupta (Executive Officer, Director), Rishi Reddy (Executive Officer, Director), Jay Santoro (Director) (SEC Form D/A, October 15, 2025).
Is this your company?
Sell to companies like Chronicle Bio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-10-15 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Chronicle Bio, Inc.
Free to see. No signup.
More on the people and the money behind Chronicle Bio, Inc., from the filings we hold.
Other Technology raises by companies based in Utah, filed in October 2025, largest first.
Get an email when Chronicle Bio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Chronicle Bio, Inc. raises, hires or launches. No email unless you switch it on.
Watch Chronicle Bio, Inc. →Get the full cited report on Chronicle Bio, Inc.
What the filing shows about Chronicle Bio, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Chronicle Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Chronicle Bio, Inc.'s address as 3535 S Market Street, Suite 900, West Valley, UT 84119.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Chronicle Bio, Inc. →
Amended on 2026-07-07: the offering size changed from $3,000,000 to $15,000,000; the amount sold changed from $2,225,000 to $10,266,000; the number of investors changed from 14 to 38. Figures on this page are from the amendment. Amended filing · Original filing
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Chronicle Bio, Inc. is a registered filer with the SEC (CIK 2090889) and has filed since 2025-10-15. 4 filings are on record, the latest on 2026-07-07.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Chronicle Bio, Inc.'s Form D of 2025-10-15 names Rohit Gupta, Rishi Reddy, Jay Santoro and 1 more as its officers, directors or promoters.
Its new offerings report $2.23M sold across 1 offering, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 3844 filings in Other Technology, totalled by week.
Rohit Gupta is named as Executive Officer and Director on the Form D that Chronicle Bio, Inc. filed with the SEC on 15 October 2025, one of 4 people that filing names.
Rishi Reddy is named as Executive Officer and Director on the Form D that Chronicle Bio, Inc. filed with the SEC on 15 October 2025, one of 4 people that filing names.
Jay Santoro is named as Director on the Form D that Chronicle Bio, Inc. filed with the SEC on 15 October 2025, one of 4 people that filing names.
Fidji Simo is named as Director on the Form D that Chronicle Bio, Inc. filed with the SEC on 15 October 2025, one of 4 people that filing names.
4 people named on the filing — 2 holding an executive role and 2 as directors only.
Named as of the 2025-10-15 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Chronicle Bio, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Chronicle Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Chronicle Bio, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Chronicle Bio, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Chronicle Bio, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Chronicle Bio, Inc.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/chronicle-bio-inc-form-d-25000001